Since 1999, Soloman Shah, MD, has worked as a physician at the Gastrointestinal Medicine Associates PC in Reston, Virginia. For over 15 years, Dr. Soloman Shah has focused on liver disorders–particularly cirrhosis and hepatitis. Other liver disorders include more serious ones, such as tyrosinaemia type I.
Baylor College of Medicine and its researchers found a way to delete a disease-associated gene from tyrosinaemia type I and transform it into a benign state.
According to Dr. Karl-Dimiter Bissig, an assistant professor at the Center for Cell and Gene Therapy, the process is called metabolic pathway reprogramming. It is a relatively a new concept that focuses on the disease-associated gene rather than the disease-causing gene.
The simple explanation is that Dr. Bissig’s team rewrote the metabolic pathway to avoid having to encounter the areas of the genes that cause the tyrosinaemia type I. The usual treatment plan for the disease is drug therapy; however, the need for drugs was eliminated when the reprogramming was used on mice.